HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region  by Senserrich, Jordi et al.
Available online at www.sciencedirect.com
8) 421–429
www.elsevier.com/locate/yviroVirology 372 (200HIV-1 resistance to the anti-HIV activity of a shRNA targeting
a dual-coding region
Jordi Senserrich, Eduardo Pauls, Mercedes Armand-Ugón, Imma Clotet-Codina,
Gemma Moncunill, Bonaventura Clotet, Jose A. Esté ⁎
Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
Received 14 September 2007; returned to author for revision 8 October 2007; accepted 31 October 2007
Available online 18 December 2007
Abstract
We generated a lymphoid cell line (Sup-T1-Rev/Env) that stably expresses a 19-bp short hairpin RNA (shRNA) targeting a conserved region of
HIV-1 encoding for the Envelope and Rev proteins, which potently inhibited viral replication. However, continuous passage of HIV-1 in Sup-T1-
Rev/Env generated virus mutants able to overcome the RNAi restriction. Sequence analysis of the emerging viruses showed that mutations were
located at positions 5 and 17 of the target sequence. Both mutations are silent in the Env frame, but the mutation 5 generated an amino acid change
(V47M) in the Rev reading frame. We have analyzed the impact of these two mutations on the RNAi mechanism, showing a more crucial role of
the mutation 17 in the resistance to RNAi. We show that even targeting a conserved region of the HIV-1 genome involved in the biosynthesis of
two essential genes, env and rev, the virus could evolve to escape by single point mutations in the target sequence, without a significant fitness
cost.
© 2007 Elsevier Inc. All rights reserved.Keywords: RNA interference; HIV; Viral evolution; ResistanceIntroduction
RNA-mediated interference (RNAi) is a post-transcriptional
gene-silencing phenomenon in which double-stranded RNA
(dsRNA) may trigger the degradation of homologous mRNA in
the cytoplasm of a cell, and has become a consolidated tool for
the study of gene function (reviewed in Paroo et al., 2007; Pauls
and Este, 2004; Rana, 2007). RNAi through transient transfec-
tion of small interfering RNA (siRNA) has been widely used to
study viral and cellular gene function, to identify cellular genes
that regulate virus infection and replication (Boden et al., 2004;
Coburn and Cullen, 2002; Dave and Pomerantz, 2004;
Huelsmann et al., 2006; Lee et al., 2002; Martinez et al.,
2002a,b) and to block HIV-1 infection (Jacque et al., 2002;
Martinez et al., 2002a,b; Stevenson, 2003). Stable expression of
siRNA can be achieved using short hairpin RNAs (shRNAs)⁎ Corresponding author. Fax: +34 93 4653968.
E-mail address: jaeste@irsicaixa.es (J.A. Esté).
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doi:10.1016/j.virol.2007.10.045(Das et al., 2004). siRNA and shRNAs have been proposed as a
therapeutic alternative for the treatment of different diseases
including HIV/AIDS (de Fougerolles et al., 2007; Kim and
Rossi, 2007) and clinical trials have been planned (Li et al.,
2006). Nevertheless, HIV may escape to the antiviral effect
induced by RNAi (Boden et al., 2003; Das et al., 2004). Muta-
tions in the target sequence may generate resistance (Boden
et al., 2003; Sabariegos et al., 2006) but alternatively, insertions,
deletions or even changes in the viral RNA secondary structure
(Das et al., 2004; Westerhout et al., 2005) have been also
associated to viral escape to RNAi.
Different strategies have been proposed to prevent the
emergence of resistance against RNAi such as the combination
of the expression of a shRNA and a dominant negative protein
from a RNA polymerase II promoter (Unwalla et al., 2006),
employing optimized longer hairpin RNAs (Konstantinova
et al., 2006), using multiple siRNA or shRNAs (Anderson et al.,
2003; Gimenez-Barcons et al., 2007; Lee et al., 2005; ter Brake
et al., 2006), or a bioinformatics approach for the design of
targeting sequences (Leonard and Schaffer, 2005).
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RNAi-induced inhibition present in a lymphoid cell line (Sup-
T1-Rev/Env) that expresses a potent short hairpin RNA, which
targets a region within rev/env genes (shRev/Env) coding for
two essential viral proteins, Rev, a regulatory protein, and Env,
that mediates viral entry into the cell (Este and Telenti, 2007).
Moreover, this genomic region has been also found to be highly
accessible to the RNAi machinery (Lee et al., 2002), and it is
highly conserved among subtype B HIV-1 strains, making this
sequence a suitable candidate to interfere with HIV-1 infection.
As the target genes are essential for HIV-1 replication cycle and
there is only one possible base change that does not alter any
reading frame, resistance within the target sequence should be
hampered. Moreover, possible insertion or deletion mutants
may be unlikely to occur. In this context, we have found that
single point mutations in the shRNA targeting sequence could
overcome this highly restrictive environment in the Sup-T1-
Rev/Env cells.Fig. 1. HIV-1 replication is abrogated in Sup-T1-Rev/Env cells. (A) Scheme of the HI
in the Sup-T1-Rev/Env cells, and targets a region that codes for both env and rev gene
no differences, measured during 6 days. Mean and standard deviations of two indepe
clinical isolates 92UG024 (subtype D), 39RW024 (subtype A) and 92BR014 (subty
circles and Sup-T1-Rev/Env in triangles), measured as extracellular CA-p24 at differ
with its standard deviation.Results
HIV-1 replication is potently inhibited in Sup-T1-Rev/Env cells
To study the effect of RNAi restriction on HIV-1 replication,
Sup-T1 cells were transduced with a retroviral vector expressing
a shRNA against a highly conserved region of the rev/env gene
(shRev/Env, Fig. 1A) from the U6 RNA polymerase III
promoter, and after puromycin selection stable cells (Sup-T1-
Rev/Env) were obtained. As a control, we also generated cells
transduced with a shRNA targeting the luciferase gene (Sup-
T1-Luc). Since the RNAimachinerymay trigger off-target effects
(Pauls et al., 2007), cellular growth and cytokine expression were
measured. These results showed no differences in the cellular
division rates and an unaltered cytokine secretion profile in stably
transduced cells (Fig. 1B and data not shown). The different cell
types were infected with the HIV-1 NL4-3 strain, and the extra-
cellular CA-p24 antigen was monitored at days 3, 6 and 9 afterV-1 genomic region target by the shRev/Env. The shRev/Env is stably expressed
s. (B) Cellular growth kinetics of the three different types of Sup-T1 cells showed
ndent experiments are shown. (C) Kinetics of viral replication of NL4-3 and the
pe B) in the Sup-T1 cellular lines (Sup-T1-wt in squares, Sup-T1-Luc in solid
ent days post infection. One representative experiment of two or three is shown,
Fig. 2. Generation of HIV-1 variants resistant to RNAi. (A) NL4-3 virus was sequentially passaged in Sup-T1-Rev/Env cells every 4–5 days, and the inhibition level was monitored by measuring the extracellular CA-p24
at each passage, comparing to a virus passaged in parallel in Sup-T1-wt cells. Nucleotide and amino acid sequence at the selected passage numbers of the wt virus (passaged in Sup-T1-wt cells for 20 passages), the Rev14
virus (passaged in Sup-T1-Rev cells for 14 passages) and the Rev20 virus (passaged in Sup-T1-Rev cells for 20 passages), compared to the NL4-3 parental sequence. The region targeted by the shRev/Env is shown
inside the rectangle. (B) Kinetics of viral replication of wild-type, Rev(5) and Rev(5+17) viruses in the Sup-T1 cellular lines (Sup-T1-wt in squares, Sup-T1-Luc in solid circles and Sup-T1-Rev/Env in triangles),
measured as extracellular CA-p24 at different days post infection. Values are given as mean and standard deviations of three independent experiments. (C) Quantification of the resistance to shRev/Env. Sup-T1-wt, Sup-
T1-Luc and Sup-T1-Rev/Env cells were infected with stocks of wt (white bars), Rev(5) (stock from Rev14, grey bars) and Rev(5+17) (stock from Rev20, black bars) and extracellular CA-p24 antigen was measured at
day 4 post infection. Values are normalized to the replication level of the virus in Sup-T1-wt cells, and expressed as percentages. Mean and standard deviations of three to five independent experiments are given.
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424 J. Senserrich et al. / Virology 372 (2008) 421–429infection (Fig. 1C). Viral replication was potently inhibited in
Sup-T1-Rev/Env cells, showing a one log decrease at day 9 as
compared to control cells.
HIV-1 primary isolates from subtypes A (isolate 92UG024),
B (isolate 92BR014) and D (isolate 39RW024) were used to
infect the different types of Sup-T1 cells. The extracellular CA-
p24 antigen was evaluated at days 3, 6, 9 and 12 after infection
to obtain the viral replication kinetics shown in Fig. 1C. The
replication of the HIV-1 strain 92UG024, which has a single
mutation at the first base of the target sequence, was inhibited in
Sup-T1-Rev/Env cells by one log at day 9 post-infection, sug-
gesting that homology in the first base may be dispensable for
the shRev/Env-triggered inhibition. The HIV-1 92BR014 strain,
containing mutations at positions 1 and 10, was completely
resistant to shRev/Env, having the same replication kinetics
both in Sup-T1-Rev/Env and in control cells. Conversely, the
replication of HIV-1 39RW024 strain was inhibited in Sup-T1-
Rev/Env cells, despite having mutations at positions 11 and 15,
suggesting that the number and position of mutations in theFig. 3. The mutations present in the viruses resistant to shRev/Env also provide resista
viruses (upper lines, in blue) and the transfected siRNA (bottom lines, in red). To sim
indicated. (B) U87-CD4-CXCR4 cells were transfected with 40 nM siRNAs against w
siRev(5), siRev(17) and siRev(5+17), respectively]. 24 h later, cells were infected w
assessed by measuring the CA-p24 production in the supernatants after 3 days. Meavirus coding sequence may be relevant for resistance to RNAi
targeting Rev/Env.
Generation of HIV-1 mutants that escape to shRev/Env
To study if HIV-1 escape variants could emerge in the
severely reduced viral replication environment in Sup-T1-Rev/
Env cells, iterative viral passages were performed. Cells were
infected, and cell free supernatant was passaged every 4-5 days
for 2 months until CA-p24 production in Sup-T1-Rev/Env was
comparable to that in control cell (data not shown). Population
sequencing of proviral DNA from the different passages
(Fig. 2A) showed the emergence of mutations at position 5
(G to A) and 17 (C to T) of the target sequence. The mutation at
position 5, which emerged at passage 11, became established as
the most abundant in the viral population after passage 14 and
did not induce amino acid changes in either Env or Rev pro-
teins. The second change at position 17 appeared soon after, but
it was not established as the most abundant until passage 20.nce to siRNAs. (A) Representation of the base homologies between the different
plify, only RNA sense strands are shown, and the bases at positions 5 and 17 are
ild-type, 5-mutated, 17-mutated and (5+17)-mutated Rev/Env sequences [siRev,
ith equal CA-p24 amounts of the different viral strains, and the replication was
n and standard deviations of two or three independent experiments are shown.
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the Rev protein sequence (V47M). Mutation at position 17 is
located close to the 3′ termini of the target sequence, and no
mutations were observed in the central region of the target or at
nucleotide bases outside the target sequence (Fig. 2A).
Viral stocks of passages 14 and 20 from Sup-T1-Rev/Env cul-
tures [termed Rev(5) and Rev(5+17) viruses, respectively, due to
the position of the mutations] were normalized to similar multi-
plicity of infection (moi), and their replication kinetics in the three
types of Sup-T1 cells were monitored during 5 days (Fig. 2B).
Both wt and Rev(5) viruses were inhibited in Sup-T1-Rev/Env
cells, up to one log at days 4 and 5 post-infection.Resistance was
quantified at 4 dpi (Fig. 2C), showing wt and Rev(5) strains
strongly inhibited in Sup-T1-Rev/Env cells (by 90.3±6.4% and
94±2.5%, respectively). Conversely, Rev(5+17) replication was
only reduced by 44.2±30.6%. These results suggest that the
mutation at position 5 alone did not induce a noticeable effect on
resistance to shRNA expressed in Sup-T1-Rev/Env cells, and theFig. 4. Drug susceptibilities of HIV-1-resistant mutant strains and replication fitness
and Rev(5+17 viruses to different antiviral drugs were evaluated calculating the co
MT-4 cells in a 5-day infection assay (Effective concentration 50, EC50). EC50 are
shown. (B) MT-4 cells were infected with the same titer of wt (squares), Rev(5) (soli
in the supernatants was monitored each day to represent the replication kinetics of
shown.addition of a mutation at base 17 was required to overcome the
inhibition.
The mutations present in the shRev/Env-resistant strain also
provide resistance to siRNAs
Synthetic siRNAs against the wild-type sequence of Rev
(siRev), the Rev containing themutation at position 5 [siRev(5)],
the Rev mutated at position 17 [siRev(17)] or the double-mutant
Rev [siRev(5+17)] were transfected in U87-CD4-CXCR4 cells,
and their effect on the replication of the different viral strains
(siRNA and virus sequences are illustrated in Fig. 3A) was
evaluated in 3-day infection experiments (Fig. 3B). As expected,
the wild-type virus was inhibited almost completely by the
siRev, whereas the Rev(5+17) virus was totally resistant to this
siRNA. In fact, a single mutation either at position 5 or at
position 17 was not sufficient to generate complete resistance
with the exception of the siRev(5+17) against the Rev(5) mutantdo not differ from those of the wild-type virus. (A) Sensitivities of wt, Rev(5)
mpound concentration that inhibits the 50% of the HIV-1-induced cell death in
expressed in μg/ml. Representative values of two independent experiments are
d circles) and Rev(5+17) (triangles) viruses, and the produced CA-p24 antigen
the strains. Mean and standard deviations of two independent experiments are
426 J. Senserrich et al. / Virology 372 (2008) 421–429virus. However, the presence of mismatch did induce a notice-
able reduction in the potency of the interference effect, sug-
gesting that a single mutation (i.e. at position 5) may induce
resistance to RNAi targeting Rev/Env.
Introduction of a mutation at position 17 appears to have a
more profound effect since the lack of homology at this position
by the siRNA induced a weaker inhibition or even replication
levels similar to the controls.
Drug susceptibilities of HIV-1-resistant mutant strains and
replication capacity do not differ from those of the wild-type
virus
All virus tested were equally sensitive to known anti-HIV
drugs (Fig. 4A), suggesting that mutations conferring resistance
to shRev/Env did not affect sensitivity to HIVentry inhibitors or
AZT. These results also allowed to normalize the multiplicity
of infection of the wt and Rev/Env mutants for virus growth
experiments.
As mutations conferring drug resistance may imply a fitness
cost to HIV-1 (Armand-Ugon et al., 2003b;Menendez-Arias and
Este, 2004; Rangel et al., 2003; Richman, 2006), and the amino
acid 47 of Rev was highly conserved among HIV-1 strains, we
examined if the mutations conferring resistance to shRNA
targeting Rev/Env affected virus replication capacity. Although
apparent differences in the growth kinetics (i.e. the slope of virus
replication at exponential growth) could be observed (data not
shown), we found no significant (pN0.1) difference in the virus
produced in lymphoid cells at any given time, suggesting that
there was no significant loss of virus fitness in the resistant
strains in cells not expressing shRev/Env (Fig. 4B).
Discussion
RNA interference has been shown to be a valid approach as a
therapy against different human pathologies, including HIV/
AIDS (de Fougerolles et al., 2007; Kim and Rossi, 2007). The
high specificity for its target implies that sequence homology
between siRNA and target mRNA is required, and only a
change in one or two bases may abrogate the silencing. Due to
the nature of RNAi, viruses such as HIV-1 may avoid gene
RNAi-induced gene silencing by mutations within the targeted
region (Boden et al., 2003; Sabariegos et al., 2006). However,
shRev/Env is directed to a dual-coding genomic region of the
virus, where there is only one base change that is synonymous
in both frames, and thus, it may be expected that mutations
within this region may be very difficult to occur. Nevertheless,
we show that in the presence of the inhibitor shRev/Env, HIV-1
could escape RNAi. As some authors have described that HIV-1
can evade the RNAi inhibition by mutations outside the target
region (Das et al., 2004), or even associated with changes in the
secondary structure of the viral RNA (Westerhout et al., 2005)
we also investigated if the mutant viruses we obtained had
mutations outside the target region. Nevertheless, the mutations
that we found were located in the region targeted by shRev/Env,
confirming the specificity of the RNAi mechanism. We do not
discard the possibility that other escape variants may appearfrom repeated evolution culture experiments or different experi-
mental conditions.
The mutation at position 17 changed Rev amino acid se-
quence, from Val to Met. Interestingly, this residue is highly
conserved among HIV-1 strains (virtually there is no variation
in this position, according to Los Alamos HIV Database), and
corresponds to the leucine-rich domain of this regulatory
protein. Of note, none of the mutations changed the Env frame,
which corresponds to an intracellular region of gp41, high-
lighting the importance of this region in viral replication.
In principle, both mutant positions should favor a resistant
phenotype. We observed that replication of the virus containing
the position 5 mutation could be inhibited in Sup-T1-Rev/Env
cells and that only the double-mutant virus was clearly resistant.
However, the base change at position 5 was positively selected
by the shRNA and as seen in the experiments with siRNAs,
a single mutation at position 5 did induce some degree of
resistance, suggesting a minor but relevant role of this mutation
that did not become apparent in the evaluation of the resistant
phenotype with shRNA. Alternatively, the mutation at position
5 may be required for the emergence of a second mutation that
generated a clearly resistant phenotype. In fact, it has been
shown that mutations not conferring resistance by themselves
are found frequently in double-mutant resistant viruses (Gitlin
et al., 2005).
Results also suggest that the activity of siRNA may be less
potent than that observed with shRNA allowing to evaluate
more discrete differences in susceptibility/resistance induced
by position 5, 17 or both. The efficacy of transfection or the
transient presence of siRNA molecules within the cells could
explain such differences in potency. Strikingly, virus replication
was higher for the double-mutant virus in siRev-transfected
cells as compared to mock-transfected cells. We have not found
a satisfactory explanation to this observation yet, but this
enhancing effect was not observed when siRev was tested
against wt and Rev(5) HIV-1 strains.
More information about the inhibitory mechanism can be
extracted from these experiments, indicating that mutations at
both positions 5 and 17 were needed to completely escape the
inhibition, as a single mismatch, in general, maintain some
extent of inhibition, which is in agreement with the literature
(Pusch et al., 2003). However, there are other factors beside
sequence homology, such as RNA secondary structure and
accessibility to the RISC complex (Westerhout and Berkhout,
2007), asymmetry of the siRNA (Schwarz et al., 2003) and
position (Gitlin et al., 2005; Sabariegos et al., 2006) and nature
of the mismatch (Du et al., 2005) may affect the activity of an
siRNA explaining a seemingly discrepant result observed with
the siRev(5+17) against the Rev(5) virus (i.e. only one
mismatch that induced complete resistance).
The mutations present in the Rev(5) and Rev(5+17) viruses
(for example, mutation at position 17 changed the Rev reading
frame in a highly conserved residue) could have an effect on the
replication capacity and drug-sensitivity of the mutant viruses.
However, we found no significant differences in fitness between
wild-type and mutant viruses when infecting parental or control
cells (i.e. inMT-4, Sup-T1-wt or Sup-T1-Luc cells). shRev/Env-
427J. Senserrich et al. / Virology 372 (2008) 421–429resistant viruses did not show changes in the sensitivities to the
antiviral compounds tested including the fusion inhibitors C-34
and T-20, which is in agreement with the observation that there
were no other differential mutations in the envelope genes of
these viruses that could affect sensitivity to HIVentry inhibitors.
Our results confirm that HIV may escape the antiviral activity
of RNAi by specific mutations in targeted sequence. Strategies to
prevent the emergence of resistant viruses have been suggested
and involve the targeting of conserved sequences and the simul-
taneous use of multiple siRNAs. Second generation siRNAs that
recognize the mutated target sites may be used to prevent the
emergence of resistant virus (ter Brake and Berkhout, 2005).
Sup-T1-Rev/Env cells have a potent inhibition against HIV-1
replication due to the expression of shRev/Env, which targets
two viral proteins, Rev and Env, essential for the life cycle of the
virus, although specific resistant variants may emerge from
medium-long term cultures without a significant fitness cost. In
conclusion, shRNA can be a valid alternative for a durable HIV
replication inhibition, but one should be aware of the appear-
ance of resistant variants that can overcome the restriction, even
if the target sequence is conserved and the genomic region
codes for more than one viral protein.
Materials and methods
Cells and reagents
The lymphoid cell lines Sup-T1 and MT-4 were obtained
through theMRCAIDSReagent Program. The astroglioma U87-
CD4-CXCR4 cell line was obtained from the NIH AIDS
Research and Reference Program. MT-4 and Sup-T1 cells were
grown in RPMI 1640 L-glutamine medium supplemented with
10% foetal calf serum (FCS), 10 U/ml penicillin and 10 μg/ml
streptomycin (Invitrogen, Barcelona, Spain). U87-CD4-CXCR4
cells were grown in selectivemedium [Dulbecco'sMEMmedium
supplemented with 10% FCS, 10 U/ml penicillin, 10 μg/ml
streptomycin, 0.5 mg/ml geneticin (all products from Invitrogen,
Barcelona, Spain) and 2 μg/ml puromycin (Sigma-Aldrich, Mad-
rid, Spain)]. Sup-T1-Rev/Env and Sup-T1-Luc cells were selected
in the presence of 2 μg/ml puromycin. When cells were infected,
no selective agents were added to the medium.
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), azidothymidine (AZT), and dextran sulfate
(DS) (MW 8000) were purchased from Sigma-Aldrich, T-20 was
obtained from Roche Pharma (Madrid, Spain) and C-34 was
received from the NIH AIDS Research and Reference Program.
The HIV-1 clinical isolates 92UG024 (subtype D), 39RW024
(subtypeA) and 92BR014 (subtype B)were obtained fromMRC
AIDS Reagent Program. Viral stocks were produced in MT-4
cells and extracellular HIV CA-p24 antigen was quantified with
an enzyme-linked immunoassay (INNOTEST™ HIV-antigen,
Innogenetics).
Generation of Sup-T1 cells stably expressing shRNAs
An oligonucleotide encoding shRNA directed against mRNA
of HIV-1 rev/env (shRev/Env) was based on the sequence pre-viously published (Castanotto et al., 2002; Lee et al., 2002) and
purchased from Sigma-Aldrich. An anti-luciferase encoding
oligonucleotide (shLuc) was provided by Clontech (Madrid,
Spain). The sense mRNA target sequences are as follows: HIV-1
shRev/Env 5′-GCCUGUGCCUCUUCAGCUA-3′ (position
8509–8527 relative to HXB2 genome); Renilla luciferase 5′-
UGCGUUGCUAGUACCAAC-3′. Oligonucleotides were
annealed and cloned into a pSIREN-RetroQ retroviral vector
(Clontech) downstream of the RNA pol III pU6 promoter,
according to the manufacturer's instructions. We packaged
pSIREN vectors into retroviral particles pseudotyped with the
envelope of the vesicular stomatitis virus (VSV-G) as described
before (Pauls et al., 2006). The growth of transduced cells was
similar to that of untreated cells, and there was no altered cyto-
kine secretion as measured by Cytometric Bead Assay (Pauls
et al., 2007) (data not shown).
Development of HIV-1 resistant to shRev/Env
The HIV-1 strain NL4-3 (input 1000 pg/ml) was grown
in parental Sup-T1 cells (Sup-T1-wt), Sup-T1-Luc cells or Sup-
T1-Rev/Env cells and passaged every 4–5 days into fresh
(uninfected) cells until the replication level in Sup-T1-Rev/Env
cells was comparable to that of control cells. At every passage,
cell-free supernatants and cellular pellets were frozen at −80 °C
until used. Selected viral passages from Sup-T1-wt cells (wt
virus) or Sup-T1-Rev/Env cells [Rev(5) and Rev(5+17) viruses]
were amplified by producing stocks inMT-4 cells. Cell-free viral
stock was estimated using an ELISA for antigen HIV CA-p24
detection (INNOTEST™HIV-antigen, Innogenetics). The HIV-
1 titers of the different viral stocks were evaluated in MT-4 cells
using a variation of the MTT colorimetric assay as described
before (Armand-Ugon et al., 2003a).
Evaluation of the resistance to shRev/Env in Sup-T1 cells
Wild-type, Rev(5) and Rev(5+17) viruses were titrated in
Sup-T1-wt cells by CA-p24 production at 4 days post infection
(dpi). Infections were run for 2 h at 37 °C, cells were washed
with sterile phosphate buffered saline (PBS) and seeded in 24-
well plates at a density of 250,000 cells/ml. Sup-T1-wt, Sup-T1-
Luc and Sup-T1-Rev/Env cells were infected with at the same
titer and extracellular CA-p24 antigen was followed for 5 days
by ELISA.
Evaluation of viral fitness and susceptibilities to antiviral
drugs
The replicative fitness of the different viruses were evaluated
as described before (Armand-Ugon et al., 2005, 2003a). Briefly,
MT-4 cells were infected with the different NL4-3 strains at the
same multiplicity of infection, and the extracellular CA-p24
antigen was evaluated every day during 5 days to represent the
replication kinetics.
Anti-HIV activity of control compounds (AZT, Nevirapine,
DS, T-20 and C34) were tested in MT-4 cells as described before
(Armand-Ugon et al., 2003a; Moncunill et al., 2005).
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1.2×105 U87-CD4-CXCR4 cells were seeded in 24-well
plates, and 40 nM of the following siRNAs were transfected. The
sense sequences are listed here: siRev 5′-GCCUGUGCCUCUU-
CAGCUAdTdT-3′; siRev(5) 5′-GCCUAUGCCUCUUCAGCU-
AdTdT-3′; siRev(17) 5′-GCCUGUGCCUCUUCAGUUAdTdT-
3′; siRev(5+17) 5′-GCCUAUGCCUCUUCAGUUAdTdT-3′
and siLuc 5′-CGUACGCGGAAUACUUCGAAAdTdT-3′).
Transfections were performed with Lipofectamine 2000, during
4 h in serum-free medium (Optimem, Invitrogen) following the
manufacturer's instructions; 24 h after transfection, cells were
infected with NL4-3 wt, Rev(5) and Rev(5+17) viruses, washed
with PBS and 3 days after infection, extracellular HIV CA-p24
antigen was evaluated with an ELISA (INNOTEST™ HIV-
antigen, Innogenetics).
Sequence analysis of wild-type and resistant viruses
MT-4 cellular pellets obtained from each stockwere used for the
analysis of the proviral sequence. Genomic DNA was extracted
with the QIAampDNABloodMini kit (Qiagen, Hilden, Germany)
and the env gene (from 5514 to 8910, nucleotide position relative to
HXB2) was amplified with the primers 5′-GATAAAGCCACC-
TTTGCCTAGT-3′ (positions 5514–5535) and 5′-TTCTAGGTC-
TCGAGATACTG-3′ (positions 8891–8910) using the Expand
High Fidelity PCRSystem (Roche, Barcelona, Spain). Both strands
were amplified with the BigDye Terminator v3.1 Cycle sequencing
kit (Applied Biosystems, Foster City, CA, USA) with the primers
5′-CGCAAAACCAGCAAGAAAAGA-3′ (8170–8190) and 5′-
TTTGACCACTTGCCACCCAT-3′ (8797–8816), and sequences
were collected in an ABI Prism 3100 Genetic Analyzer. Align-
ments were analyzed with Sequencher 4.6 (Gene Codes Corpora-
tion) and GeneDoc 2.6 (Nicholas et al., 1997) software.
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